Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is N/A as of Tuesday, October 6, 2026.
GROSS MARGIN
N/A
Market Cap
$561.54M
Gross Margin
98.63%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$547.30M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$578.53M
Gross Margin
67.04%
TTM Avg
65.22%
3Y Avg
62.15%
5Y Avg
65.14%
Market Cap
$539.41M
Gross Margin
-195.10%
TTM Avg
-90.32%
3Y Avg
-3207.95%
5Y Avg
-2168.95%
Market Cap
$538.76M
Gross Margin
82.92%
TTM Avg
86.33%
3Y Avg
62.04%
5Y Avg
41.36%
Market Cap
$583.51M
Gross Margin
73.65%
TTM Avg
72.81%
3Y Avg
73.64%
5Y Avg
74.48%
Market Cap
$584.01M
Gross Margin
35.58%
TTM Avg
39.19%
3Y Avg
43.45%
5Y Avg
55.13%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.54M | 98.63% | 100.00% | 100.00% | 100.00% |
| CorMedix Inc. (CRMD)vs › | $570.74M | 82.78% | 90.56% | 68.85% | 51.96% |
| Monopar Therapeutics Inc. (MNPR)vs › | $547.30M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $578.53M | 67.04% | 65.22% | 62.15% | 65.14% |
| Shattuck Labs, Inc. (STTK)vs › | $539.41M | -195.10% | -90.32% | -3207.95% | -2168.95% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $538.76M | 82.92% | 86.33% | 62.04% | 41.36% |
| OrthoPediatrics Corp. (KIDS)vs › | $583.51M | 73.65% | 72.81% | 73.64% | 74.48% |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.01M | 35.58% | 39.19% | 43.45% | 55.13% |
| Delcath Systems, Inc. (DCTH)vs › | $535.19M | 87.05% | 84.77% | 78.39% | 75.97% |
Gross Margin
N/A
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
